杭州梧桐树药业

Sycamore Pharma is a clinical-stage biotechnology company based in Hangzhou, China, specializing in the development of innovative small molecule drugs for metabolic and oncological diseases. The company's lead candidate, WTS101, is a highly selective thyroid hormone receptor beta (THR-beta) agonist currently undergoing Phase 2 clinical trials for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Sycamore Pharma aims to provide best-in-class therapeutic solutions by targeting well-validated biological pathways with optimized chemical structures to improve safety and efficacy. Led by a team of experienced drug hunters, the company has successfully secured significant venture capital funding to advance its pipeline. Its strategic focus remains on addressing high-prevalence diseases with significant unmet medical needs in both the Chinese and global markets.